Journal article
AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).
- Marme, Frederik AGO & National Center for Tumor Disease/Department of Gynecology, University of Heidelberg, Heidelberg, Germany;
- Pautier, Patricia GINECO & Gustave Roussy Cancer Center, Villejuif, France;
- Van Nieuwenhuysen, Els BGOG & Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium;
- Reuss, Alexander AGO & Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany;
- Redondo, Andres GEICO & Hospital Universitario La Paz, Madrid, Spain;
- Lindemann, Kristina NSGO & Oslo University Hospital, Oslo, Norway;
- Kurzeder, Christian SAKK & University Hospital Basel, Basel, Switzerland;
- Marth, Christian AGO-Austria & Medical University of Innsbruck, Innsbruck, Austria;
- Burges, Alexander AGO & Department of Gynecology, University Hospital Munich-Großhadern, Munich, Germany;
- Pietzner, Klaus AGO & Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany;
- Wimberger, Pauline AGO & Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany;
- De Gregorio, Nikolaus AGO & Department of Gynecology and Obstetrics, University of Ulm, Ulm, Germany;
- Harter, Philipp AGO & Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany;
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2019, vol. 37, no. 15_suppl, p. TPS5601-TPS5601
English
TPS5601 Background: A standard non-platinum based treatment option in patients with relapsed ovarian cancer is bevacizumab in combination with paclitaxel or pegylated liposomal doxorubicin, but responses are still short-lived. Checkpoint-inhibitors as single agent have limited activity in ovarian cancer. However, the role of the checkpoint-inhibitor like atezolizumab, in addition to chemotherapy and bevacizumab in ovarian cancer is so far undefined. Methods: AGO-OVAR 2.29 is a randomized (1:1), double blinded, phase III trial evaluating the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy (weekly paclitaxel or pegylated liposomal doxorubicin) compared with placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum-based chemotherapy or 3rd relapse. A tumor biopsy available at study entry for PD-L1 testing is mandatory. Patients are treated with chemotherapy plus bevacizumab +/- atezolizumab/placebo until progression or prohibitive toxicity. Co-primary endpoints are overall survival and progression-free survival. It is planned to randomize 664 patients. A safety interim analysis will be done when 24 patients have been randomized and completed at least cycle 1. As of 1st February 2019, 24 patients have been randomized. Clinical trial information: NCT03353831.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1200/jco.2019.37.15_suppl.tps5601
- ISSN 0732-183X
- Persistent URL
- https://sonar.ch/global/documents/109845
Statistics
Document views: 15
File downloads: